RxDoctor Payments Data

Judith Frank, MD

Rheumatology · Melrose Park, ILNPI 1407929144

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 47 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$608
  • Johnson & Johnson$201
  • Amgen$201
  • UCB, Inc.$155
  • Lilly USA, LLC$86
  • GSK$82
  • plus $76 from 3 others

What the payments were for

  • Consulting fees$403%
  • Speaking & faculty fees$35025%
  • Food & beverage$90564%
  • Education$1148%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$608
Johnson & Johnson7$201
Amgen6$201
UCB, Inc.8$155
Lilly USA, LLC4$86
GSK3$82
AstraZeneca3$45
Radius Health, Inc.1$17
Pfizer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 50th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$395,925
Medicare patients
127
Services billed
43,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab58$408,954
Enbrel SureclickEtanercept47$365,897
Humira PenAdalimumab26$170,356
OtezlaApremilast17$105,435
Xeljanz XrTofacitinib Citrate15$83,773
OrenciaAbatacept/Maltose15$66,220
MethotrexateMethotrexate Sodium246$5,682
Hydroxychloroquine Sulfate189$4,943
Leflunomide38$2,371
Colchicine35$1,413
Celecoxib38$1,241
Prednisone123$944
Tramadol Hcl50$282
Methotrexate SodiumMethotrexate Sodium/Pf21$222
Allopurinol13$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$201$105,43517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Melrose Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →